SynAct Pharma AB Stock Price

OM:SYNACT Community·SEK 1.3b Market Cap

0 Narratives written by author
0 Comments on narratives written by author
4 Fair Values set on narratives written by author

Create a narrative

SYNACT Share Price Performance

SEK 23.80

14.84 (165.48%)

SEK 23.80

14.84 (165.48%)

SEK 23.80

Sun, 28 Dec 25

Share Pricen/a

SYNACT Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

High growth potential with adequate balance sheet.

2 Risks

1 Reward

View Full Analysis

SynAct Pharma AB Key Details

Last Reported Earnings

Sep 30, 2025

Next Reporting Earnings

Feb 18, 2026

: -1.99
: 0%
: 0%
: 0%

View Full Analysis

About SYNACT

Founded: 2012
Employees: 8
CEO: Jeppe Ovlesen
WebsiteView website: synactpharma.com

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.